These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 39171954)
1. Systemic Multifunctional Nanovaccines for Potent Personalized Immunotherapy of Acute Myeloid Leukemia. Zhang P; Wang T; Cui G; Ye R; Wan W; Liu T; Zheng Y; Zhong Z Adv Mater; 2024 Oct; 36(40):e2407189. PubMed ID: 39171954 [TBL] [Abstract][Full Text] [Related]
2. Glucosylated Nanovaccines for Dendritic Cell-Targeted Antigen Delivery and Amplified Cancer Immunotherapy. Liu J; Cui Y; Cabral H; Tong A; Yue Q; Zhao L; Sun X; Mi P ACS Nano; 2024 Sep; 18(37):25826-25840. PubMed ID: 39196858 [TBL] [Abstract][Full Text] [Related]
3. Tumor-Associated Myeloid Cells Selective Delivery of a Therapeutic Tumor Nano-Vaccine for Overcoming Immune Barriers for Effective and Long-Term Cancer Immunotherapy. Wang C; Zhao J; Duan Y; Lin L; Zhang Q; Zheng H; Shan W; Wang X; Ren L Adv Healthc Mater; 2024 Oct; 13(26):e2401416. PubMed ID: 38848734 [TBL] [Abstract][Full Text] [Related]
4. Uplifting Antitumor Immunotherapy with Lymph-Node-Targeted and Ratio-Controlled Codelivery of Tumor Cell Lysate and Adjuvant. Cui G; Sun Y; Qu L; Shen C; Sun Y; Meng F; Zheng Y; Zhong Z Adv Healthc Mater; 2024 Jul; 13(17):e2303690. PubMed ID: 38458152 [TBL] [Abstract][Full Text] [Related]
5. Genetically Engineered Cytomembrane Nanovaccines for Cancer Immunotherapy. Pan Y; Wu X; Liu L; Zhao C; Zhang J; Yang S; Pan P; Huang Q; Zhao XZ; Tian R; Rao L Adv Healthc Mater; 2024 May; 13(13):e2400068. PubMed ID: 38320299 [TBL] [Abstract][Full Text] [Related]
6. Conjugation of TLR7 Agonist Combined with Demethylation Treatment Improves Whole-Cell Tumor Vaccine Potency in Acute Myeloid Leukemia. Zhong G; Jin G; Zeng W; Yu C; Li Y; Zhou J; Zhang L; Yu L Int J Med Sci; 2020; 17(15):2346-2356. PubMed ID: 32922200 [No Abstract] [Full Text] [Related]
7. A carrier-free nanovaccine combined with cancer immunotherapy overcomes gemcitabine resistance. Pan W; Wang Y; Chen G; Ma X; Min Y Biomaterials; 2025 Feb; 313():122788. PubMed ID: 39236628 [TBL] [Abstract][Full Text] [Related]
8. Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses. Weigel BJ; Panoskaltsis-Mortari A; Diers M; Garcia M; Lees C; Krieg AM; Chen W; Blazar BR Exp Hematol; 2006 Oct; 34(10):1403-12. PubMed ID: 16982333 [TBL] [Abstract][Full Text] [Related]
9. Targeted Codelivery of an Antigen and Dual Agonists by Hybrid Nanoparticles for Enhanced Cancer Immunotherapy. Zhang L; Wu S; Qin Y; Fan F; Zhang Z; Huang C; Ji W; Lu L; Wang C; Sun H; Leng X; Kong D; Zhu D Nano Lett; 2019 Jul; 19(7):4237-4249. PubMed ID: 30868883 [TBL] [Abstract][Full Text] [Related]
10. A Biomimetic Autophagosomes-Based Nanovaccine Boosts Anticancer Immunity. Qu L; Cui G; Sun Y; Ye R; Sun Y; Meng F; Wang S; Zhong Z Adv Mater; 2024 Oct; 36(40):e2409590. PubMed ID: 39194369 [TBL] [Abstract][Full Text] [Related]
11. PLGA- Cao Q; Zhou R; Guo S; Meng K; Yang X; Liu M; Ma B; Su C; Duan X Int J Nanomedicine; 2024; 19():9437-9458. PubMed ID: 39290859 [TBL] [Abstract][Full Text] [Related]
12. Nanovaccines for cancer immunotherapy: Focusing on complex formation between adjuvant and antigen. Hashemi Goradel N; Nemati M; Bakhshandeh A; Arashkia A; Negahdari B Int Immunopharmacol; 2023 Apr; 117():109887. PubMed ID: 36841155 [TBL] [Abstract][Full Text] [Related]
13. Quantitative expression of Toll-like receptor-2, -4, and -9 in dendritic cells generated from blasts of patients with acute myeloid leukemia. Schmitt A; Li L; Giannopoulos K; Greiner J; Reinhardt P; Wiesneth M; Schmitt M Transfusion; 2008 May; 48(5):861-70. PubMed ID: 18208411 [TBL] [Abstract][Full Text] [Related]
14. Dendritic cell-based nanovaccines for cancer immunotherapy. Paulis LE; Mandal S; Kreutz M; Figdor CG Curr Opin Immunol; 2013 Jun; 25(3):389-95. PubMed ID: 23571027 [TBL] [Abstract][Full Text] [Related]
15. Manganese oxide-constructed multifunctional biomimetic nanovaccine for robust tumor-specific T cell priming and chemodynamic therapy. Li T; Chen G; Lin L; Li B; Wang X; Chen Y; Huang W; Cai M; Xiao Z; Shuai X; Zhu K Biomaterials; 2024 Sep; 309():122626. PubMed ID: 38795524 [TBL] [Abstract][Full Text] [Related]
16. Immunotherapy and Prevention of Cancer by Nanovaccines Loaded with Whole-Cell Components of Tumor Tissues or Cells. Ma L; Diao L; Peng Z; Jia Y; Xie H; Li B; Ma J; Zhang M; Cheng L; Ding D; Zhang X; Chen H; Mo F; Jiang H; Xu G; Meng F; Zhong Z; Liu M Adv Mater; 2021 Oct; 33(43):e2104849. PubMed ID: 34536044 [TBL] [Abstract][Full Text] [Related]
17. Engineered Nanoparticles for Cancer Vaccination and Immunotherapy. Aikins ME; Xu C; Moon JJ Acc Chem Res; 2020 Oct; 53(10):2094-2105. PubMed ID: 33017150 [TBL] [Abstract][Full Text] [Related]
18. Dual-Targeted Self-Adjuvant Heterocyclic Lipidoid@Polyester Hybrid Nanovaccines for Boosting Cancer Immunotherapy. Liu Z; Liu B; Feng Y; Zhao L; Wang Q; He H; Yin T; Zhang Y; Yang L; Gou J; Tang X ACS Nano; 2024 Jun; 18(24):15557-15575. PubMed ID: 38837909 [TBL] [Abstract][Full Text] [Related]
19. New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia. Subklewe M; Geiger C; Lichtenegger FS; Javorovic M; Kvalheim G; Schendel DJ; Bigalke I Cancer Immunol Immunother; 2014 Oct; 63(10):1093-103. PubMed ID: 25186611 [TBL] [Abstract][Full Text] [Related]
20. Enhanced antitumor immunity by targeting dendritic cells with tumor cell lysate-loaded chitosan nanoparticles vaccine. Shi GN; Zhang CN; Xu R; Niu JF; Song HJ; Zhang XY; Wang WW; Wang YM; Li C; Wei XQ; Kong DL Biomaterials; 2017 Jan; 113():191-202. PubMed ID: 27816821 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]